NEW YORK, Feb. 17 (GenomeWeb News) - Human Metabolome Technologies of Yamagata, Japan, yesterday announced a biomarker research collaboration with Mitsubishi Pharma.
Under the terms of the agreement, HMT will search for biomarkers for the early detection of drug-induced phospholipidosis using its metabolomics tools, which include capillary-electrophoresis and mass spectrometry technology for small-molecule separation and detection.
Financial details of the agreement were not disclosed.